March 16 (Reuters) – Moderna Inc began dosing patients in an intermediate-to-end study of its COVID-19 vaccine, mRNA-1273, in children six months to under 12, the company said on Tuesday .
The study will evaluate the safety and efficacy of two doses of mRNA-1273 administered 28 days apart and aims to enroll about 6,750 children in the United States and Canada.
The vaccine has already been authorized for emergency use in Americans aged 18 and over.
In a separate study that began in December, Moderna is also testing mRNA-1273 in adolescents between 12 and 18 years old.
The latest study is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) and the Advanced Biomedical Research and Development Authority (BARDA). (Reporting by Manojna Maddipatla in Bengaluru; Editing by Shailesh Kuber)